Lu M, Amano S, Miyamoto K, Garland R, Keough K, Qin W, Adamis AP
Investigative ophthalmology & visual science
Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol Vis Sci. 1999 Dec; 40(13):3281-6.
Insulin-induced vascular endothelial growth factor expression in retina.
Moromizato Y, Stechschulte S, Miyamoto K, Murata T, Tsujikawa A, Joussen AM, Adamis AP
CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury. Am J Pathol. 2000 Oct; 157(4):1277-81.
CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury.
Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci. 2001 Mar; 42(3):789-94.
Sensitive blood-retinal barrier breakdown quantitation using Evans blue.
Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP
VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003 May; 44(5):2155-62.
VEGF164 is proinflammatory in the diabetic retina.
Ambati BK, Joussen AM, Kuziel WA, Adamis AP, Ambati J
Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea. 2003 Jul; 22(5):465-7.
Inhibition of corneal neovascularization by genetic ablation of CCR2.
Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004 Sep; 18(12):1450-2.
A central role for inflammation in the pathogenesis of diabetic retinopathy.
Ellenberg D, Shi J, Jain S, Chang JH, Ripps H, Brady S, Melhem ER, Lakkis F, Adamis A, Chen DF, Ellis-Behnke R, Langer RS, Strittmatter SM, Azar DT
Impediments to eye transplantation: ocular viability following optic-nerve transection or enucleation. Br J Ophthalmol. 2009 Sep; 93(9):1134-40.
Impediments to eye transplantation: ocular viability following optic-nerve transection or enucleation.
Wroblewski JJ, Wells JA, Adamis AP, Buggage RR, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Altaweel MM
Archives of ophthalmology (Chicago, Ill. : 1960)
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol. 2009 Apr; 127(4):374-80.
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
Anterior corneal disease of epidermolysis bullosa simplex. Arch Ophthalmol. 1993 Apr; 111(4):499-502.
Anterior corneal disease of epidermolysis bullosa simplex.
The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc
Denovo development of corneal guttae and Fuchs' dystrophy in corneal grafts. CLAO J. 2000 Jan; 26(1):44-6.
Denovo development of corneal guttae and Fuchs' dystrophy in corneal grafts.
Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D'Amore PA
The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem. 1996 Feb 16; 271(7):3877-83.
The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences.
Annals of the New York Academy of Sciences
Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci. 2006 Oct; 1082:151-71.
Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.
Treatment options for periorbital hemangioma of infancy. Int Ophthalmol Clin. 1992; 32(3):95-109.
Treatment options for periorbital hemangioma of infancy.
Moore TC, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Adamis AP
The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci. 2003 Oct; 44(10):4457-64.
The role of advanced glycation end products in retinal microvascular leukostasis.
Zahn G, Vossmeyer D, Stragies R, Wills M, Wong CG, Löffler KU, Adamis AP, Knolle J
Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol. 2009 Oct; 127(10):1329-35.
Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization.
Adamis AP, Filatov V, Tripathi BJ, Tripathi RC
Fuchs' endothelial dystrophy of the cornea. Surv Ophthalmol. 1993 Sep-Oct; 38(2):149-68.
Fuchs' endothelial dystrophy of the cornea.
Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996 Jan; 114(1):66-71.
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate.
Chakravarthy U, Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Patel M
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006 Sep; 113(9):1508.e1-25.
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, Moromizato Y, Bursell SE, Wiegand SJ, Rudge J, Ioffe E, Yancopoulos GD, Adamis AP
Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol. 2002 May; 160(5):1683-93.
Suppression of diabetic retinopathy with angiopoietin-1.
Greene AK, Wiener S, Puder M, Yoshida A, Shi B, Perez-Atayde AR, Efstathiou JA, Holmgren L, Adamis AP, Rupnick M, Folkman J, O'Reilly MS
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg. 2003 Apr; 237(4):530-5.
Endothelial-directed hepatic regeneration after partial hepatectomy.
Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP
Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci. 2007 Feb; 48(2):858-65.
Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology. 2007 Sep; 114(9):1702-12.
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, Yeo KT
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994 Oct 15; 118(4):445-50.
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.
Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, Folkman J, D'Amore PA
Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995 Jan; 1(2):182-93.
Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen.
Safety during the transition to phacoemulsification: a survey. Int Ophthalmol Clin. 1994; 34(3):51-65.
Safety during the transition to phacoemulsification: a survey.
Zahn G, Volk K, Lewis GP, Vossmeyer D, Stragies R, Heier JS, Daniel PE, Adamis AP, Chapin EA, Fisher SK, Holz FG, Löffler KU, Knolle J
Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. Invest Ophthalmol Vis Sci. 2010 Feb; 51(2):1028-35.
Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment.
Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998 Nov-Dec; 43(3):245-69.
Ocular neovascularization: an epidemiologic review.
Ghiso N, Rohan RM, Amano S, Garland R, Adamis AP
Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest Ophthalmol Vis Sci. 1999 May; 40(6):1033-9.
Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP.
Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994 Sep; 145(3):574-84.
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.
Adamis AP, Shima DT, Yeo KT, Yeo TK, Brown LF, Berse B, D'Amore PA, Folkman J
Biochemical and biophysical research communications
Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun. 1993 Jun 15; 193(2):631-8.
Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells.
Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP
Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci. 2003 Jan; 44(1):290-9.
Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres.
Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996 Aug; 114(8):964-70.
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate.
Adamis AP, Molnar ML, Tripathi BJ, Emmerson MS, Stefansson K, Tripathi RC
Neuronal-specific enolase in human corneal endothelium and posterior keratocytes. Exp Eye Res. 1985 Nov; 41(5):665-8.
Neuronal-specific enolase in human corneal endothelium and posterior keratocytes.
Current clinical topics in infectious diseases
Infections of the eyelid, lacrimal system, conjunctiva, and cornea. Curr Clin Top Infect Dis. 1996; 16:125-50.
Infections of the eyelid, lacrimal system, conjunctiva, and cornea.
Angiogenic factors in the development of diabetic iris neovascularization and retinopathy. Int Ophthalmol Clin. 1998; 38(1):77-94.
Angiogenic factors in the development of diabetic iris neovascularization and retinopathy.
Guyer DR, Adamis AP, Gragoudas ES, Folkman J, Slakter JS, Yannuzzi LA
Systemic antiangiogenic therapy for choroidal neovascularization. What is the role of interferon alfa? Arch Ophthalmol. 1992 Oct; 110(10):1383-4.
Systemic antiangiogenic therapy for choroidal neovascularization. What is the role of interferon alfa?
Ambati J, Canakis CS, Miller JW, Gragoudas ES, Edwards A, Weissgold DJ, Kim I, Delori FC, Adamis AP
Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000 Apr; 41(5):1181-5.
Diffusion of high molecular weight compounds through sclera.
Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Döhmen S, Adamis AP
Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002 Mar; 16(3):438-40.
Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression.
Husain D, Ambati B, Adamis AP, Miller JW
Mechanisms of age-related macular degeneration. Ophthalmol Clin North Am. 2002 Mar; 15(1):87-91.
Mechanisms of age-related macular degeneration.
Angiogenesis and ophthalmic disease. Angiogenesis. 1999; 3(1):9-14.
Arcadu F, Benmansour F, Maunz A, Michon J, Haskova Z, McClintock D, Adamis AP, Willis JR, Prunotto M
Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color Fundus Photographs. Invest Ophthalmol Vis Sci. 2019 03 01; 60(4):852-857.
Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color Fundus Photographs.
Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, Chiang Y, Ehrlich JS, Erickson S, Hanley WD, Horvath J, Maass KF, Singh N, Tang F, Barteselli G
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. Ophthalmology. 2019 08; 126(8):1141-1154.
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
Charles L. Schepens Professor of Ophthalmology
David Glendenning Cogan Professor of Ophthalmology
Paul Austin Chandler Professor of Ophthalmology
Charles Webster Downer Professor of Ophthalmology
Charles Edward Whitten Distinguished Professor of Ophthalmology
A. Werk Cook Professor of Radiation Oncology (Tumor Biology)
Adamis AP, Brittain CJ, Dandekar A, Hopkins JJ
Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye (Lond). 2020 11; 34(11):1966-1972.
Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade.
Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2022 03; 129(3):295-307.
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 02 19; 399(10326):741-755.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Development of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2022 May 01; 33(3):131-136.
Development of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration.
Tumlinson AR, Calara JM, Azar DT, Adamis AP, Vavvas DG, Stewart JM
Feasibility demonstration of a device for vitreous liquid biopsy incidental to intravitreal injection. PLoS One. 2024; 19(1):e0294526.
Feasibility demonstration of a device for vitreous liquid biopsy incidental to intravitreal injection.
Hartnett ME, Fickweiler W, Adamis AP, Brownlee M, Das A, Duh EJ, Feener EP, King G, Kowluru R, Luhmann UFO, Storti F, Wykoff CC, Aiello LP
Rationale of Basic and Cellular Mechanisms Considered in Updating the Staging System for Diabetic Retinal Disease. Ophthalmol Sci. 2024 Sep-Oct; 4(5):100521.
Rationale of Basic and Cellular Mechanisms Considered in Updating the Staging System for Diabetic Retinal Disease.
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013 Oct; 120(10):2013-22.
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
Nagai N, Lundh von Leithner P, Izumi-Nagai K, Hosking B, Chang B, Hurd R, Adamson P, Adamis AP, Foxton RH, Ng YS, Shima DT
Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction. Invest Ophthalmol Vis Sci. 2014 May 20; 55(6):3709-19.
Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction.
Targeting the Effect of VEGF in Diabetic Macular Edema. N Engl J Med. 2015 07 30; 373(5):480-1.
Targeting the Effect of VEGF in Diabetic Macular Edema.
Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors. Dev Ophthalmol. 2016; 55:28-37.
Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors.
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016 06; 15(6):385-403.
Ten years of anti-vascular endothelial growth factor therapy.
ENDOGENOUS STIMULATION OF CORNEAL NEOVASCULARIZATION
ENDOGENOUS INHIBITION OF OCULAR ANGIOGENESIS
Huang SH, Adamis AP, Wiederschain DG, Shima DT, Shing Y, Moses MA
Matrix metalloproteinases and their inhibitors in aqueous humor. Exp Eye Res. 1996 May; 62(5):481-90.
Matrix metalloproteinases and their inhibitors in aqueous humor.
Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, Adamis AP
Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996 Oct 01; 98(7):1667-75.
Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.
Nicaeus TE, Tolentino MJ, Adamis AP, Rubin PA
Ophthalmic plastic and reconstructive surgery
Sucralfate and basic fibroblast growth factor promote endothelial cell proliferation around porous alloplastic implants in vitro. Ophthalmic Plast Reconstr Surg. 1996 Dec; 12(4):235-9.
Sucralfate and basic fibroblast growth factor promote endothelial cell proliferation around porous alloplastic implants in vitro.
Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996 Nov; 103(11):1820-8.
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.
Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy NS, Goldberg MA, D'Amato RJ, Adamis AP
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 1997 Oct; 46(10):1619-26.
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I.
Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res. 2002 Mar; 21(2):145-51.
Transscleral drug delivery to the retina and choroid.
Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. Ophthalmol Clin North Am. 2002 Mar; 15(1):69-79.
Vascular endothelial growth factor gene regulation and action in diabetic retinopathy.
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005 Jun; 40(3):352-68.
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb; 5(2):123-32.
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP
Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998 Jan; 39(1):18-22.
Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.
Lu M, Perez VL, Ma N, Miyamoto K, Peng HB, Liao JK, Adamis AP
VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999 Jul; 40(8):1808-12.
VEGF increases retinal vascular ICAM-1 expression in vivo.
Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K, Gillies S, O'Reilly MS, Adamis AP
Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol. 2002 Aug; 120(8):1063-8.
Angiostatin inhibits and regresses corneal neovascularization.
A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis. Ophthalmology. 2000 Aug; 107(8):1512-7.
A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis.
Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP
Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998 Mar 15; 101(6):1219-24.
Advanced glycation end products increase retinal vascular endothelial growth factor expression.
Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, Adamis AP
Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000 May; 156(5):1733-9.
Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1).
Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998 Feb; 105(2):232-7.
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma.
Chlamydial ocular diseases. Int Ophthalmol Clin. 1998; 38(1):221-30.
Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, Ju ST, Rook SL, Esser P, Mitsiades CS, Kirchhof B, Adamis AP, Aiello LP
Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J. 2003 Jan; 17(1):76-8.
Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes.
Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J, Wiegand SJ, Yancopoulos GD, Adamis AP
VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci. 2003 Jan; 44(1):117-23.
VEGF-dependent conjunctivalization of the corneal surface.
Yamashiro K, Tsujikawa A, Ishida S, Usui T, Kaji Y, Honda Y, Ogura Y, Adamis AP
Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am J Pathol. 2003 Jul; 163(1):253-9.
Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown.
Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci. 2004 Feb; 45(2):368-74.
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.
Shedding light on diabetic retinopathy. Ophthalmology. 1995 Aug; 102(8):1127-8.
Kim I, Ryan AM, Rohan R, Amano S, Agular S, Miller JW, Adamis AP
Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999 Aug; 40(9):2115-21.
Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes.
Abiko T, Abiko A, Clermont AC, Shoelson B, Horio N, Takahashi J, Adamis AP, King GL, Bursell SE
Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes. 2003 Mar; 52(3):829-37.
Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation.
Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002 Feb; 160(2):501-9.
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.
Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002 Mar; 120(3):338-46.
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.
Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest. 2002 Mar; 109(6):805-15.
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF.
Conjunctival concretions. Am J Ophthalmol. 1992 Nov 15; 114(5):640-1.
Ambati BK, Anand A, Joussen AM, Kuziel WA, Adamis AP, Ambati J
Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci. 2003 Feb; 44(2):590-3.
Sustained inhibition of corneal neovascularization by genetic ablation of CCR5.
Angiogenesis inhibition in age-related macular degeneration. Ophthalmology. 1995 Sep; 102(9):1261-2.
Angiogenesis inhibition in age-related macular degeneration.
Hofman P, Blaauwgeers HG, Tolentino MJ, Adamis AP, Nunes Cardozo BJ, Vrensen GF, Schlingemann RO
VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. Curr Eye Res. 2000 Aug; 21(2):637-45.
VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A.
Ciardella AP, Donsoff IM, Guyer DR, Adamis A, Yannuzzi LA
Antiangiogenesis agents. Ophthalmol Clin North Am. 2002 Dec; 15(4):453-8.
Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP
VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001 Sep; 42(10):2408-13.
VEGF-initiated blood-retinal barrier breakdown in early diabetes.
Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003 May-Jun; 48(3):257-93.
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.
Judah Folkman. Semin Ophthalmol. 2009 May-Jun; 24(3):128-9.
Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR
Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30; 351(27):2805-16.
Pegaptanib for neovascular age-related macular degeneration.
Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES, Ng YS, D'Amore PA, Shima DT, Adamis AP
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003 Aug 04; 198(3):483-9.
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.
D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006 Jun; 113(6):992-1001.e6.
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol. 2007; 39:122-148.
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy.
Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health. 2008 Jul-Aug; 11(4):563-74.
Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscinskas FW, Adamis AP
Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 2000 Apr; 41(5):1153-8.
Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes.
Afshari NA, Mullally JE, Afshari MA, Steinert RF, Adamis AP, Azar DT, Talamo JH, Dohlman CH, Dryja TP
Survey of patients with granular, lattice, avellino, and Reis-Bücklers corneal dystrophies for mutations in the BIGH3 and gelsolin genes. Arch Ophthalmol. 2001 Jan; 119(1):16-22.
Survey of patients with granular, lattice, avellino, and Reis-Bücklers corneal dystrophies for mutations in the BIGH3 and gelsolin genes.
The rationale for drug combinations in age-related macular degeneration. Retina. 2009 Jun; 29(6 Suppl):S42-4.
The rationale for drug combinations in age-related macular degeneration.
In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. Am J Pathol. 1991 Nov; 139(5):961-7.
In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells.
Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006 Jun; 168(6):2036-53.
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.
Jo N, Ju M, Nishijima K, Robinson GS, Adamis AP, Shima DT, Mailhos C
Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization. Mol Vis. 2006 Oct 26; 12:1243-9.
Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization.
Shima DT, Gougos A, Miller JW, Tolentino M, Robinson G, Adamis AP, D'Amore PA
Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci. 1996 Jun; 37(7):1334-40.
Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis.
Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, Shima DT, Robinson GS, Ng YS
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci. 2007 Mar; 48(3):1212-8.
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.
Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011 Aug; 118(8):1594-602.
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
Stechschulte SU, Joussen AM, von Recum HA, Poulaki V, Moromizato Y, Yuan J, D'Amato RJ, Kuo C, Adamis AP
Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci. 2001 Aug; 42(9):1975-9.
Rapid ocular angiogenic control via naked DNA delivery to cornea.
Moore JE, McMullen TC, Campbell IL, Rohan R, Kaji Y, Afshari NA, Usui T, Archer DB, Adamis AP
The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest Ophthalmol Vis Sci. 2002 Sep; 43(9):2905-15.
The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy.
The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005 Feb-Mar; 25(2):111-8.
The role of vascular endothelial growth factor in ocular health and disease.
Lutty GA, Chan-Ling T, Phelps DL, Adamis AP, Berns KI, Chan CK, Cole CH, D'Amore PA, Das A, Deng WT, Dobson V, Flynn JT, Friedlander M, Fulton A, Good WV, Grant MB, Hansen R, Hauswirth WW, Hardy RJ, Hinton DR, Hughes S, McLeod DS, Palmer EA, Patz A, Penn JS, Raisler BJ, Repka MX, Saint-Geniez M, Shaw LC, Shima DT, Smith BT, Smith LE, Tahija SG, Tasman W, Trese MT
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis. 2006 May 23; 12:532-80.
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California).
Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am. 2006 Sep; 19(3):323-34.
Molecular biology of choroidal neovascularization.
Loughman MS, Chatzistefanou K, Gonzalez EM, Flynn E, Adamis AP, Shing Y, D'Amato RJ, Folkman J
Australian and New Zealand journal of ophthalmology
Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor. Aust N Z J Ophthalmol. 1996 Aug; 24(3):289-95.
Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor.
Kaji Y, Amano S, Usui T, Oshika T, Yamashiro K, Ishida S, Suzuki K, Tanaka S, Adamis AP, Nagai R, Horiuchi S
Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci. 2003 Feb; 44(2):521-8.
Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells.
Adamis AP, Altaweel M, Bressler NM, Cunningham ET, Davis MD, Goldbaum M, Gonzales C, Guyer DR, Barrett K, Patel M
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006 Jan; 113(1):23-8.
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.
Ocular delivery of angiostatic agents. Int Ophthalmol Clin. 2004; 44(3):41-51.
Tolentino MJ, Husain D, Theodosiadis P, Gragoudas ES, Connolly E, Kahn J, Cleland J, Adamis AP, Cuthbertson A, Miller JW
Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch Ophthalmol. 2000 Jan; 118(1):78-84.
Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization.
Ambati J, Gragoudas ES, Miller JW, You TT, Miyamoto K, Delori FC, Adamis AP
Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000 Apr; 41(5):1186-91.
Transscleral delivery of bioactive protein to the choroid and retina.
Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008 Apr; 30(2):65-84.
Immunological mechanisms in the pathogenesis of diabetic retinopathy.
Ishida S, Yamashiro K, Usui T, Kaji Y, Ogura Y, Hida T, Honda Y, Oguchi Y, Adamis AP
Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med. 2003 Jun; 9(6):781-8.
Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease.
Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol. 2004 Aug; 165(2):457-69.
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.
Avellino corneal dystrophy. Arch Ophthalmol. 1994 Mar; 112(3):418-9.
Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol. 2008 Dec; 92(12):1606-11.
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.
Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007 Jul; 171(1):53-67.
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.
Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G, Calias P, Lange N, Adamis AP, Shima DT, Robinson GS
Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest Ophthalmol Vis Sci. 2008 Feb; 49(2):662-70.
Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.
Advances in experimental medicine and biology
The case for complement and inflammation in AMD: open questions. Adv Exp Med Biol. 2010; 703:1-7.
The case for complement and inflammation in AMD: open questions.
Primary acquired melanosis of the conjunctiva. Int Ophthalmol Clin. 1997; 37(4):61-72.
Primary acquired melanosis of the conjunctiva.
Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP
Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001 Jan; 158(1):147-52.
Leukocyte-mediated endothelial cell injury and death in the diabetic retina.
Götte M, Joussen AM, Klein C, Andre P, Wagner DD, Hinkes MT, Kirchhof B, Adamis AP, Bernfield M
Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci. 2002 Apr; 43(4):1135-41.
Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature.
Moore JE, McMullen CB, Mahon G, Adamis AP
The corneal epithelial stem cell. DNA Cell Biol. 2002 May-Jun; 21(5-6):443-51.
Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, Adamis AP, Ambati J
Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jun; 44(6):2743-9.
Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization.
Pournaras CJ, Miller JW, Gragoudas ES, Husain D, Munoz JL, Tolentino MJ, Kuroki M, Adamis AP
Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch Ophthalmol. 1997 Dec; 115(12):1553-8.
Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina.
Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005 Oct; 112(10):1747-57.
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP
Proceedings of the National Academy of Sciences of the United States of America
Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999 Sep 14; 96(19):10836-41.
Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition.
Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, Meyer TN, Poulaki V, Ma JJ, Redmond TM, Liu S, Adamis AP, D'Amato RJ
Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol. 2001 Mar; 158(3):1161-72.
Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium.
Joussen AM, Huang S, Poulaki V, Camphausen K, Beecken WD, Kirchhof B, Adamis AP
In vivo retinal gene expression in early diabetes. Invest Ophthalmol Vis Sci. 2001 Nov; 42(12):3047-57.
In vivo retinal gene expression in early diabetes.
Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA
Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol. 2002 Mar; 133(3):373-85.
Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate.
Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002 Apr; 86(4):363-5.
Is diabetic retinopathy an inflammatory disease?
Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997 Mar; 13(1):37-50.
Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy.
Retinal manifestations of aging. Int Ophthalmol Clin. 1998; 38(1):95-101.